SCHEMBL402082

SCHEMBL402082

COC(=O)c1ccc(OC(=O)CCCc2ccc(NC(=O)c3cccnc3-c3ccc(C(F)(F)F)cc3)c(C(=O)N(C)C)c2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.38
TRPV1 Q8NER1 6/20 0.38
PPARG P37231 2/20 0.36
PPARA Q07869 2/20 0.36
PPARD Q03181 1/20 0.36
NR1H4 Q96RI1 1/20 0.36
P2RY1 P47900 1/20 0.36
PLK1 P53350 1/20 0.36
SLC2A1 P11166 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
AURKA O14965 1/20 0.35
ABL1 P00519 1/20 0.35
EGFR P00533 1/20 0.35
NTRK1 P04629 1/20 0.35
INSR P06213 1/20 0.35
LCK P06239 1/20 0.35
FES P07332 1/20 0.35
CSF1R P07333 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL400448 0.93 TRPV1 (0.38) KCNH2TRPV1PPARGPPARAPPARD
SCHEMBL10205546 0.89 NTRK1 (0.42) KCNH2PPARGPPARAPPARDNR1H4
SCHEMBL5319240 0.89 MTTP (0.46) PPARGPPARAPPARDNR1H4KMT2A
SCHEMBL403302 0.86 KLRK1 (0.40) KCNH2PPARGPPARAPLK1SLC2A1
SCHEMBL401591 0.85 PPARG (0.38) KCNH2PPARGPPARAPLK1MTTP
SCHEMBL402584 0.84 MTTP (0.38) KCNH2PPARGPPARAPPARDNR1H4
SCHEMBL403078 0.84 MTTP (0.47) PPARGPPARAPPARDNR1H4KMT2A
SCHEMBL399294 0.84 MTTP (0.43) MAPK14MTTP
SCHEMBL402266 0.84 NTRK1 (0.43) KCNH2PPARGPPARAPPARDNR1H4
SCHEMBL403565 0.83 MTTP (0.41) PPARGPPARAPPARDNR1H4PLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1803452-A1 ESTER DERIVATIVE AND PHARMACEUTICAL USE THEREOF Japan Tobacco, Inc. (JP) 2007-07-04 EP claimed
US-20060089392-A1 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2006-04-27 US claimed
US-8101774-B2 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2012-01-24 US disclosed
US-8101774-B2 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2012-01-24 US disclosed
US-8101774-B2 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2012-01-24 US disclosed
EP-1803452-A1 ESTER DERIVATIVE AND PHARMACEUTICAL USE THEREOF Japan Tobacco, Inc. (JP) 2007-07-04 EP disclosed
US-20060089392-A1 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2006-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089392-A1 Ester derivatives and medicinal use thereof MTTP, CETP, LIPA KCNH2 4171/4885TRPV1 2345/4885PPARG 322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.